China Biotech In Review: Cellular Biomedicine To Reverse Merger In U.S. [View article]
Thanks for the article on CBMG. One correction - the deal isactually not a reverse merger by SEC standards. It's a normal merger. Reverse merger requires a pickle period of one year on OTC and satisfying other compliance requirements during the pickle period.
China Biotech In Review: Cellular Biomedicine To Reverse Merger In U.S. [View article]
How Apple's iPad, 3D Printing Suggest Bio-Printing Technology Is Finally Here [View article]
TG Therapeutics: Biotech Suitors Not Waiting For Clinical Results [View article]
Excellent post. Thanks for writing.
Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye [View article]
Organovo Seeks To Clean Up Balance Sheet, Execute On Its Model [View article]